Harpoon Therapeutics Inc. shares surged as much as 40% in pre-market trading on Monday after the clinical-stage immunotherapy company announced that its lung cancer drug (HPN328) showed "promising" antitumor activity and tolerability profile in a Phase 1/2 clinical trial.
Harpoon said the preliminary response data for evaluable patients treated in one milligram priming dose cohorts showed a confirmed response rate of 35% across all tumor types.
"The interim data provides a solid foundation for the next steps in our future clinical development plans for HPN328, underscoring its potential to serve patients with high unmet medical needs," Harpoon Therapeutics chief medical officer Luke Walker said in a statement.
"It enables us to rapidly move towards identifying the recommended Phase 2 regimen(s) in the monotherapy setting by the end of this year and supports the initiation of potential registrational studies in multiple tumor types in 2024," he added.
Harpoon noted that with enrollment in monotherapy dose cohorts nearing completion, it is on track to select Phase 2 dose(s) by the end of 2023.
The company added that results will be presented in a poster session at European Society of Medical Oncology (ESMO) Congress 2023 on October 23, 2023, and management will hold a webcast at 8 AM EDT to review the data, following the poster presentation.
Contact Sean at sean@proactiveinvestors.com